Big Data and Real-World Data based Cost-Effectiveness Studies and Decision-making Models: A Systematic Review and Analysis

Abstract

Background: Big data and real-world data (RWD) have been increasingly used to measure the effectiveness and costs in cost-effectiveness analysis (CEA). However, the characteristics and methodologies of CEA based on big data and RWD remain unknown. The objectives of this study were to review the characteristics and methodologies of the CEA studies based on big data and RWD and to compare the characteristics and methodologies between the CEA studies with or without decision-analytic models. Methods: The literature search was conducted in Medline (Pubmed), Embase, Web of Science, and Cochrane Library (as of June 2020). Full CEA studies with an incremental analysis that used big data and RWD for both effectiveness and costs written in English were included. There were no restrictions regarding publication date. Results: 70 studies on CEA using RWD (37 with decision-analytic models and 33 without) were included. The majority of the studies were published between 2011 and 2020, and the number of CEA based on RWD has been increasing over the years. Few CEA studies used big data. Pharmacological interventions were the most frequently studied intervention, and they were more frequently evaluated by the studies without decision-analytic models, while those with the model focused on treatment regimen. Compared to CEA studies using decision-analytic models, both effectiveness and costs of those using the model were more likely to be obtained from literature review. All the studies using decision-analytic models included sensitivity analyses, while four studies no using the model neither used sensitivity analysis nor controlled for confounders. Conclusion: The review shows that RWD has been increasingly applied in conducting the cost-effectiveness analysis. However, few CEA studies are based on big data. In future CEA studies using big data and RWD, it is encouraged to control confounders and to discount in long-term research when decision-analytic models are not used.

Using real world evidence to generate cost-effectiveness analysis of fibrinolytic therapy in patients with ST-segment elevation myocardial infarction in Thailand

“… 39 , 40 As a result, a cost effectiveness analysis may be more applicable to a health system if the local data are used as input parameters. 41 Real-world evidence has been recognized for its strength in answering the actual questions based on real-world data and widely encouraged in informing treatment reimbursement decision-making. 42 Various countries worldwide including those in Asia have used real-world evidence to support their national health policy.…”

A scoping review on quality assessment tools used in systematic reviews and meta-analysis of real-world studies

“…Only one [23] of the included studies utilised very specific tools for methodological quality assessment. Three [24][25][26] of the included studies employed validated QA tools. In order to validate the tools used in the included studies, they employed 39 non-randomised studies [24], 131 cohort studies [25] and 30 cost-effectiveness studies [26].…”

“…Three [24][25][26] of the included studies employed validated QA tools. In order to validate the tools used in the included studies, they employed 39 non-randomised studies [24], 131 cohort studies [25] and 30 cost-effectiveness studies [26]. On the other hand, the QA tools utilised to the remaining thirteen of the included studies were not validated.…”

Greece 2.0, Health Economics and Outcome Research and the Rise of Artificial Intelligence: Another Missed Opportunity or it's Time for Brilliance?

“…This means that additional studies should be conducted throughout the technology's lifecycle, from trials to RWD, which is not an easy task given the need to use sophisticated methods to efficiently analyse large amounts of healthcare data (Lu et al, 2021). By applying innovative methods to large volumes of healthcare data, AI and its applications such as machine learning (ML) have the potential to generate real breakthroughs in both HEOR and patient care and management.…”